Recent Updates
Recently added Catalysts
RNXT Positive Sentiment

RenovoRx’s TAMP Platform Will Deliver Imugene’s CF33 Oncolytic Virotherapy in Companies’ Research Collaboration

Thursday, July 20, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: RenovoRx and Imugene have formed a strategic research collaboration to enhance the delivery of Imugene's CF33 oncolytic virus therapy using RenovoRx's TAMP platform. This partnership aims to optimize treatment for challenging tumors, leveraging both companies' innovative technologies. The collaboration highlights the potential for improved cancer therapies through targeted delivery methods.
Price reaction · baseline $2.08 (2023-07-19 close) · hit pre-market · 1 other RNXT headline(s) in the window, move may be shared
day 0 close · peak
+3.8%

Market Sentiment Analysis

POSITIVE FACTORS

  • Collaboration aims to enhance cancer treatment options.
  • Utilizes innovative TAMP therapy platform for delivery.
  • Focus on difficult-to-access tumors shows promise.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+57%
120-day peak, hindsight
Typical move
12.3%
average across 4 past catalysts
Cash runway
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxel
Phase 3 · Locally Advanced Pancreatic Cancer

Full Press Release Details

July 20, 2023—RenovoRx, Inc., a Los Altos, California-based clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Limited, a clinical-stage immuno-oncology company headquartered in Sydney, Australia, announced a strategic research collaboration to optimize the delivery of Imugene’s oncolytic virus therapy with RenovoRx’s transarterial microperfusion (TAMP) therapy platform for the treatment of difficult-to-access tumors.
As part of the collaboration, Imugene and RenovoRx will investigate the ability to administer Imugene’s CF33 oncolytic virus technology with RenovoRx’s TAMP therapy platform.
View the entire article on Endovascular Today

Frequently Asked Questions

What is the purpose of the RenovoRx and Imugene collaboration?

The collaboration aims to optimize the delivery of Imugene's CF33 oncolytic virus therapy using RenovoRx's TAMP platform.

What technology will be used in the collaboration?

The collaboration will utilize RenovoRx's transarterial microperfusion (TAMP) therapy platform.

What type of tumors are targeted in this research?

The research focuses on difficult-to-access tumors.

Where is RenovoRx based?

RenovoRx is based in Los Altos, California.

What is Imugene's focus area?

Imugene is focused on immuno-oncology therapies.

ShareAdd on Google
Tags: RNXT Viatris Investor Conferences Healthcare RenovoRx Imugene CF33 TAMP therapy oncology
Last updated: Jul 20, 2023

Biotech snapshot

Cash runway
$9M liquidity · $1M/mo burn
~10 mo
Medium dilution risk
Lead asset
nab-paclitaxelPhase 3
Locally Advanced Pancreatic Cancer →

Catalyst track record

+57%
best trade around RNXT's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for RNXT.

See every catalyst's timing & PoA →